Global CAR-T Cell Therapy Treatment Market is expected to grow with the CAGR of 30.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:
Global CAR-T cell therapy treatment market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in global CAR-T cell therapy treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in July 2020, Kite Pharma (a subsidiary of Gilead Sciences, Inc.) had received the U.S.FDA approval for Tecartus the only approved CAR-T cell therapy for the treatment of refractory mantle cell lymphoma (MCL). The product has been also granted with Breakthrough Therapy Designation (BTD) from the U.S. FDA. This approval paved the way for the product approval and allowed it to expand its root in the CAR-T cell therapy treatment market.
Kite Pharma (a subsidiary of Gilead Sciences, Inc.) is the dominating player in global CAR-T cell therapy treatment market. The other key players existing in the CAR-T cell therapy treatment market are Autolus, Atara Biotherapeutics, Inc., Amgen Inc., Bellicum Phamaceuticals, Inc., bluebird bio, inc., Adaptimmune Therapeutics plc, Bristol-Myers Squibb Company, Xyphos (a subsidiary of Astellas Pharma Inc.), Johnson & Johnson Services, Inc., BioAtla Inc., AbbVie Inc., Novartis AG, Aurora Biopharma, Tmunity Therapeutics, Cartherics Pty ltd, CARINA BIOTECH, Ziopharm Oncology, Inc., Cellectis SA, Mustang Bio, Sorrento Therapeutics, Inc., Cartesian Therapeutics, Inc., TC BioPharm Limited, Celyad Oncology SA, Tessa Therapeutics Ltd. among others.
Kite Pharma (a subsidiary of Gilead Sciences, Inc.):
Kite Pharma (a subsidiary of Gilead Sciences, Inc.) is headquartered in California, U.S. and was founded in 2009. The company is focused on the cell therapy by using genetically modified immune cells to target the tumors and the company wants to change the methods for treating the cancer. The company deals in multiple business segments such as HIV products, HCV products, veklury, cell therapy products, trodelvy and other products among which cell therapy products is the market focused segment. The company provides products under categories such as technology and our therapies in which our technology is the market focused category.
The company has wide presence across North America and Europe. The company also has various subsidiary companies including Cell Design Labs, Inc. (U.S.), Fosun Kite Biotechnology Co., Ltd (China) and others.
Novartis AG is headquartered in Basel, Switzerland and was founded in 1996. The company focuses on innovating new solutions for various health care challenges. The company operates its business via two business segments including innovative medicines and Sandoz in which innovative medicines is the market focused segment. The company has wide range of products under categories which are cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience and respiratory in which cancer is the market focused category.
The company has presence across Americas, Asia-Pacific, Europe and Middle East and Africa. The company also has various subsidiaries including Novartis Argentina S.A. (Argentina), Novartis Australia Pty Ltd (Australia), Novartis Austria GmbH (Austria), Novartis Pharma NV (Belgium), Sandoz (China) Pharmaceutical (China) among others.
Global CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028
Asia-Pacific CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028
Middle East and Africa CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028
Europe CAR-T Cell Therapy Treatment Market – Industry Trends and Forecast to 2028
North America CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028